Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 9 Jan 2024 |
| Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons | 3 Jan 2024 |
| Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference | 2 Jan 2024 |
| Genmab A/S has published its Articles of Association | 13 Dec 2023 |
| Genmab to Hold 2023 R&D Update and ASH Data Review Meeting | 12 Dec 2023 |